FDA Approves Supplemental Application for Butrans by KNOA Pharma
The FDA has approved a supplemental application for Butrans, which contains buprenorphine as the active ingredient.
Asset / Drug
Drug and asset intelligence for Butrans with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Topline Data
Monitor for any additional labeling changes or new indications that may arise from this supplemental approval.
June 27, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.